Medtronic (MDT, 2M6) β†’ Stock, financial statements
Advertising

Medtronic

Dividends News
Favorites
  • 2M6, MDT Ticker
  • πŸ‡ΊπŸ‡Έ NYSE, πŸ‡©πŸ‡ͺ XETRA Exchange
  • 86,368 Employees
26 rated
comming soon
comming soon
comming soon
comming soon
comming soon
comming soon
comming soon
comming soon
comming soon

Financial statements β€” Medtronic

The information is not 100% up-to-date. There may be errors or missing information. Some information is often missing, and, although there are almost no errors, I can't rule them out. Right now, I'm looking for a supplier of high-quality information, but so far what I'm finding is expensive (about $2000 a year). You can help my project here.
21 ← 16 2021 2020 2019 2018 2017 2016
Total Revenue
30B 29B 31B 30B 30B 29B
Cost Of Revenue
10B 9.4B 9.2B 9.1B 9.3B 9.1B
Gross Profit
20B 19B 21B 21B 20B 20B
Research and Development
2.5B 2.3B 2.3B 2.3B 2.2B 2.2B
Selling General and Admin
10B 10B 10B 10B 9.7B 9.5B
Operating Expense
25B 24B 24B 23B 23B 23B
Operating Income
4.9B 5.2B 6.6B 6.8B 6.5B 6.1B
Other Income Expense Net
0 0 0 0 0 0
EBIT
4.9B 5.2B 6.6B 6.8B 6.5B 6.1B
Interest Income
930M 1.1B 1.4B 750M 730M 960M
Pretax Income
3.9B 4.1B 5.2B 5.7B 4.6B 4.3B
Income Tax
270M -750M 550M 2.6B 580M 800M
Minority Interest
24M 17M 19M -9M -4M 0
Net Income
3.6B 4.8B 4.6B 3.1B 4B 3.5B
Net Income Basic
3.6B 4.8B 4.6B 3.1B 4B 3.5B
21 ← 16 2021 2020 2019 2018 2017 2016
Current cash
11B 11B 9.8B 11B 14B 13B
Short term investments
2B 2.2B 2.1B 2.2B 1.9B 1.2B
Receivables
5.5B 4.6B 6.2B 6B 5.6B 5.6B
Inventory
4.3B 4.2B 3.8B 3.6B 3.3B 3.5B
Other current assets
2B 2.2B 2.1B 2.2B 1.9B 1.2B
Current assets
23B 22B 22B 23B 25B 24B
Long term investments
71B 69B 68B 68B 75B 76B
Property plant equipment
5.2B 4.8B 4.7B 4.6B 4.4B 4.8B
Goodwill
42B 40B 40B 40B 39B 42B
Intangible assets
18B 19B 21B 22B 23B 27B
Other assets
1.8B 1.6B 640M 730M 640M 1.6B
Total assets
93B 91B 90B 91B 100B 100B
Accounts payable
2.1B 2B 2B 1.6B 1.7B 1.7B
Current long term debt
11M 2.8B 840M 2.1B 7.5B 990M
Other current liabilities
6.4B 5.6B 5.7B 6.4B 5B 4.5B
Total current liabilities
8.5B 10B 8.5B 10B 14B 7.2B
Long term debt
26B 22B 24B 24B 26B 30B
Other liabilities
5.6B 6.3B 5.2B 5.4B 5.6B 6.6B
Minority Interest
170M 140M 120M 100M 120M 0
Total Liabilities
42B 40B 40B 41B 50B 48B
Common stock
1.3B 1.3B 1.3B 1.4B 1.4B 1.4B
Retained earning
29B 28B 26B 24B 23B 54B
Treasury stock
0 0 0 0 0 0
Capital surplus
β€’ β€’ β€’ β€’ β€’ β€’
Shareholder equity
51B 51B 50B 51B 50B 52B
Net tangible assets
-8.3B -8.2B -10B -11B -12B -16B
21 ← 16 2021 2020 2019 2018 2017 2016
Net Income
3.6B 4.8B 4.6B 3.1B 4B 3.5B
Depreciation
2.7B 2.7B 2.7B 2.6B 2.9B 2.8B
Changes in receivables
820M -1.6B 240M 400M 29M 450M
Changes in inventories
84M 480M 170M 240M -140M 10M
Cash change
-130M 1.1B -1.4B -2.5B 1.1B -6.8B
Cash flow
6.2B 7.2B 7B 4.7B 6.9B 5.2B
Capital expenditures
-1.4B -1.2B -1.1B -1.1B -1.3B -1B
Investments
β€’ β€’ β€’ β€’ β€’ β€’
Investing activity other
β€’ β€’ β€’ β€’ β€’ β€’
Total investing cash flows
-2.9B -3.2B -770M 5.9B -1.6B 2.2B
Dividends paid
β€’ β€’ β€’ β€’ β€’ β€’
Net borrowings
14B 12B 13B 12B 18B 17B
Other financing cash flows
β€’ β€’ β€’ β€’ β€’ β€’
Cash flow financing
-4.1B -4.2B -5.4B -12B -3.3B -9.5B
Exchange rate effect
β€’ β€’ β€’ β€’ β€’ β€’

Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. It operates through the following segments: Cardiac and Vascular Group; Minimally Invasive Technologies Group; Restorative Therapies Group; and Diabetes Group. The Cardiac and Vascular Group segment consist Cardiac Rhythm and Heart Failure, Coronary and Structural Heart, and Aortic and Peripheral Vascular divisions. The Minimally Invasive Technologies Group segment comprises Surgical Innovations and Respiratory, Gastrointestinal, and Renal divisions. The Restorative Therapies Group contains Spine, Brain, Specialty Therapies, and Pain Therapies divisions. The Diabetes Group segment focuses in the development, manufacturing, and marketing of products and services for the management of Type I and Type II diabetes. The company was founded in 1949 and is headquartered in Dublin, Ireland.